Ivabradine
8,081 views
Cardiovascular Pharm (Old)
- Adenosine
- Magnesium
- Nitroprusside
- Nitrates
- Ivabradine
- Digoxin/Digitalis
- Class IA Antiarrhythmics
- Class IB Antiarrhythmics
- Class IC Antiarrhythmics
- Class II Antiarrhythmics
- Class III Antiarrhythmics - Amiodarone
- Class III Antiarrythmics - Sotalol
- Class III Antiarrhythmics - Ibutilide, Dofetilide
- Class IV Antiarrhythmics - Verapamil, Diltiazem
- HMG-CoA Reductase Inhibitors (Statins)
- Ezetimibe
- Fibrates
- PCSK9 Inhibitors (Alirocumab, Evolocumab)
- Fish Oil and Omega-3s
- Milrinone
- Aliskiren
- Hydralazine
- Ranolazine
- Sacubitril
Summary
Ivabradine decreases heart rate without affecting the heart's contractility. It works by decreasing sodium flow across funny channels, which decreases SA node firing and subsequently slows the heart rate. Since it does not affect inotropy, it can be used to treat angina and systolic heart failure in patients who can’t be on a beta-blocker. Adverse effects include a luminous phenomenon, which is caused by inhibition of ion channels in the retina that resemble funny channels.
Key Points
- Ivabradine
- Mechanism
- Selective inhibition of funny channels
- Prolongs the slow depolarization phase (phase 4) of the pacemaker potential
- Decreases SA node firing
- Negative chronotropic effect without inotropy
- Reduces cardiac O2 requirement
- Selective inhibition of funny channels
- Clinical Use
- Chronic stable angina in patients who cannot take B-blockers
- Chronic heart failure with reduced ejection fraction
- Adverse Effects
- Luminous phenomenon / visual brightness
- Caused by inhibition of ion channels in the retina that are similar to funny channels
- Bradycardia
- Luminous phenomenon / visual brightness
- Mechanism